290 related articles for article (PubMed ID: 35880977)
21. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
26. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
28. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Malhaire C; Selhane F; Saint-Martin MJ; Cockenpot V; Akl P; Laas E; Bellesoeur A; Ala Eddine C; Bereby-Kahane M; Manceau J; Sebbag-Sfez D; Pierga JY; Reyal F; Vincent-Salomon A; Brisse H; Frouin F
Eur Radiol; 2023 Nov; 33(11):8142-8154. PubMed ID: 37318605
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.
Yoen H; Kim SY; Lee DW; Lee HB; Cho N
Korean J Radiol; 2023 Jul; 24(7):626-639. PubMed ID: 37404105
[TBL] [Abstract][Full Text] [Related]
30. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
[TBL] [Abstract][Full Text] [Related]
31. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Onishi N; Bareng TJ; Gibbs J; Li W; Price ER; Joe BN; Kornak J; Esserman LJ; Newitt DC; Hylton NM; ;
Radiol Imaging Cancer; 2023 Jul; 5(4):e220126. PubMed ID: 37505107
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
[TBL] [Abstract][Full Text] [Related]
33. Utility of
Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
[TBL] [Abstract][Full Text] [Related]
34. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
35. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
36. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
37. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
38. Four-Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast-Enhanced MRI.
Caballo M; Sanderink WBG; Han L; Gao Y; Athanasiou A; Mann RM
J Magn Reson Imaging; 2023 Jan; 57(1):97-110. PubMed ID: 35633290
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers.
Ramtohul T; Djerroudi L; Lissavalid E; Nhy C; Redon L; Ikni L; Djelouah M; Journo G; Menet E; Cabel L; Malhaire C; Tardivon A
Radiology; 2023 Aug; 308(2):e222646. PubMed ID: 37526540
[TBL] [Abstract][Full Text] [Related]
40. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy.
Mazari FAK; Sharma N; Dodwell D; Horgan K
Radiology; 2018 Aug; 288(2):366-374. PubMed ID: 29786482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
